£4.8M
The extension brings total Series C financing to £18.8m with participation from US investor Modi Ventures.
Brainomix
Artificial intelligence software for medical imaging diagnostics.
£34.8MTotal raised
Brainomix develops artificial intelligence imaging software designed to improve clinical diagnostics for strokes and lung fibrosis. The medtech firm emerged from academic research at the University of Oxford.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Cash, assets and headcount from Brainomix's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Team
Michalis Papadakis
CEO
Michalis is the CEO and co-founder of Brainomix and previously served as a scientific director at the University of Oxford. He also contributes to advisory groups including the National AI Commission and the BioIndustry Association.
LinkedInJH
Jackie Hunter
Chair
AB
Alastair Buchan
Professor of Stroke Medicine
Investors
- £4.8M
- £14.0M
- £16.0M
Funding history
£14.0M
The Series C round was co-led by Parkwalk Advisors and the Boehringer Ingelheim Venture Fund to support international expansion and clinical studies.
£16.0M
The financing round was co-led by Boehringer Ingelheim Venture Fund and Parkwalk Advisors, with participation from Tencent and Oxford University Innovation Fund.